First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301).Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301.The combination was well-tolerated at all tested dose levels.Data to be presented by National Cancer Institute as an oral presentation at Cytokines 2023.

首次研究转移性前列腺癌患者评估标准化疗（多西紫杉醇）联合抗体药物偶联物（PDS0301）。在所有三种测试剂量的PDS0301中，所有患者均观察到前列腺特异性抗原（PSA）水平降低。在所有测试剂量水平下，该组合具有良好的耐受性。国家癌症研究所提供的数据作为细胞因子2023的口头报告。

PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced interim safety and immune response data for the first-in-human Phase 1/2 clinical trial evaluating PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with current standard-of-care (SOC) chemotherapy, docetaxel, to treat metastatic castration sensitive (mCSPC) and castration resistant (mCRPC) prostate cancer.

新泽西州普林斯顿，2023年10月11日（GLOBE NEWSWIRE）-PDS生物技术公司（纳斯达克股票代码：PDSB）（PDS Biotech或该公司），一家临床阶段免疫治疗公司，开发越来越多的靶向癌症免疫疗法和传染病疫苗管道基于该公司专有的T细胞激活平台，今天宣布了首次人体1/2期临床试验的临时安全性和免疫应答数据，该试验评估PDS0301，一种新型研究性肿瘤靶向，抗体偶联白细胞介素12，结合现行护理标准（SOC）化疗，多西紫杉醇，治疗转移性去势敏感（mCSPC）和去势抵抗（mCRPC）前列腺癌。

The data will be featured in an oral presentation by Ravi A. Madan, MD, Head, Prostate Cancer Clinical Research Section, Genitourinary Malignancies Branch, Center for Cancer Research of the National Cancer Institute, an Institute of the National Institutes of Health, at the 11th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2023) in Athens, Greece.

这些数据将在Ravi A.Madan，医学博士，前列腺癌临床研究部负责人，泌尿生殖系统恶性肿瘤分部，国家癌症研究所癌症研究中心，国立卫生研究院研究所的口头报告中得到特色。国际细胞因子和干扰素学会（细胞因子2023）第11届年会在希腊雅典举行。

“We are encouraged by the preliminary data from the Phase 1/2 clinical trial evaluating PDS0301 in combination with docetaxel for patients with metastatic prostate cancer which has the potential to improve treatment outcomes for patients with advanced and refractory prostate cancers th.

“我们对1/2期临床试验评估PDS0301联合多西紫杉醇治疗转移性前列腺癌患者的初步数据感到鼓舞，该试验有可能改善晚期和难治性前列腺癌患者的治疗效果。